Acquired resistance to the TRK inhibitor entrectinib in colorectal cancer

Cancer Discovery

Volumn 6, Issue 1, 2016, Pages 36-44

  Russo, Mariangela ^a,b,c   Misale, Sandra ^b   Wei, Ge ^d   Siravegna, Giulia ^a,b   Crisafulli, Giovanni ^b   Lazzari, Luca ^a,b   Corti, Giorgio ^b   Rospo, Giuseppe ^b   Novara, Luca ^b   Mussolin, Benedetta ^b   Bartolini, Alice ^b   Cam, Nicholas ^d   Patel, Roopal ^d   Yan, Shunqi ^d   Shoemaker, Robert ^d   Wild, Robert ^d   di Nicolantonio, Federica ^a,b   Sartore Bianchi, Andrea ^e   Li, Gang ^d   Siena, Salvatore ^e,f   Bardelli, Alberto ^a,b   more..

^a UNIVERSITY OF TURIN   (Italy)

^b IRCCS   (Italy)

^c FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^d Ignyta   (United States)

^e OSPEDALE NIGUARDA CA GRANDA   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; ENTRECTINIB; LAMIN A; LOXO 101; PROTEIN TYROSINE KINASE INHIBITOR; TROPOMYOSIN; TSR 011; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; INDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE A; TRKA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CELL VIABILITY ASSAY; COLORECTAL CANCER; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA ISOLATION; GENE; GENE EXPRESSION PROFILING; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LMNA GENE; MOUSE; NEXT GENERATION SEQUENCING; NONHUMAN; NTRK1 GENE; POLYMERASE CHAIN REACTION; WESTERN BLOTTING; ANIMAL; CANCER TRANSPLANTATION; CHEMISTRY; COLORECTAL NEOPLASMS; DRUG RESISTANCE; ENZYME ACTIVE SITE; GENE REARRANGEMENT; GENETICS; MUTATION; PATHOLOGY; TUMOR CELL LINE; TUMOR EMBOLISM;

ANIMALS; BENZAMIDES; CATALYTIC DOMAIN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; GENE REARRANGEMENT; HUMANS; INDAZOLES; MICE; MUTATION; NEOPLASM TRANSPLANTATION; NEOPLASTIC CELLS, CIRCULATING; PROTEIN KINASE INHIBITORS; RECEPTOR, TRKA;

EID: 84954060726     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-15-0940     Document Type: Article

References (28)

1. Vaishnavi A, Le AT, Doebele RC. TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 2015; 5: 25-34.
2. Shaw AT, Hsu PP, Awad MM, Engelman JA. Tyrosine kinase gene rearrangements in epithelial malignancies. Nat Rev Cancer 2013; 13: 772-87.
3. Siena S, Drilon AE, Ou S-HI, Farago AF, Patel M, Bauer TM, et al. Entrectinib (RXDX-101), an oral pan-Trk, ROS1, and ALK inhibitor in patients with advanced solid tumors harboring gene rearrangements. Eur J Cancer 2015; 50: Supplement 3.
4. Sartore-Bianchi A, Ardini E, Bosotti R, Amatu A, Valtorta E, Somaschini A, et al. Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer. J Natl Cancer Int 2016; 108. [Epub ahead of print].
5. Ardini E, Bosotti R, Borgia AL, De Ponti C, Somaschini A, Cammarota R, et al. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition. Mol Oncol 2014; 8: 1495-507.
6. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 2013; 19: 1469-72.
7. Medico E, Russo M, Picco G, Cancelliere C, Valtorta E, Corti G, et al. The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets. Nat Commun 2015; 6: 7002.
8. Siravegna G, Bardelli A. Genotyping cell-free tumor DNA in the blood to detect residual disease and drug resistance. Genome Biol 2014; 15: 449.
9. Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-6.
10. Siravegna G, Mussolin B, Buscarino M, Corti G, Cassingena A, Crisafulli G, et al. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients. Nat Med 2015; 21: 795-801.
11. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, M akarewicz AJ, et al. High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 2011; 83: 8604-10.
12. Reinert T, Schøler LV, Thomsen R, Tobiasen H, Vang S, Nordentoft I, et al. Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. Gut 2015. [Epub ahead of print].
13. Stransky N, Cerami E, Schalm S, Kim JL, Lengauer C. The landscape of kinase fusions in cancer. Nat Commun 2014; 5: 4846.
14. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, et al. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 2014; 5: 3116.
15. Bounacer A, Schlumberger M, Wicker R, Du-Villard JA, Caillou B, Sarasin A, et al. Search for NTRK1 proto-oncogene rearrangements in human thyroid tumours originated after therapeutic radiation. Br J Cancer 2000; 82: 308-14.
16. Overman MJ, Modak J, Kopetz S, Murthy R, Yao JC, Hicks ME, et al. Use of research biopsies in clinical trials: are risks and benefits adequately discussed? J Clin Oncol 2013; 31: 17-22.
17. Friboulet L, Li N, Katayama R, Lee CC, Gainor JF, Crystal AS, et al. The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 2014; 4: 662-73.
18. Katayama R, Friboulet L, Koike S, Lockerman EL, Khan TM, Gainor JF, et al. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib. Clin Cancer Res 2014; 20: 5686-96.
19. Zou HY, Friboulet L, Kodack DP, Engstrom LD, Li Q, West M, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell 2015; 28: 70-81.
20. Doebele RC, Davis LE, Vaishnavi A, Le AT, Estrada-Bernal A, Keysar S, et al. An oncogenic NTRK fusion in a patient with soft-tissue sarcoma with response to the tropomyosin-related kinase inhibitor LOXO-101. Cancer Discov 2015; 5: 1049-57.
21. Wilcoxen KM, inventor; Tesaro, Inc., assignee. Modulating certain tyrosine kinases. United States patent US wo2013074518a1 2013 May 23.
22. Hayden RT, Gu Z, Ingersoll J, Abdul-Ali D, Shi L, Pounds S, et al. Comparison of droplet digital PCR to real-time PCR for quantitative detection of cytomegalovirus. J Clin Microbiol 2013; 51: 540-6.
23. Li H, Durbin R. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-95.
24. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 2009; 25: 2078-9.
25. Conway T, Wazny J, Bromage A, Tymms M, Sooraj D, Williams ED, et al. Xenome-a tool for classifying reads from xenograft samples. Bioinformatics 2012; 28: i172-8.
26. Wu CH, Apweiler R, Bairoch A, Natale DA, Barker WC, Boeckmann B, et al. The Universal Protein Resource (UniProt): an expanding universe of protein information. Nucleic Acids Res 2006; 34 (Database issue): D187-91.
27. Edgar RC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 2004; 5: 113.
28. Waterhouse AM, Procter JB, Martin DM, Clamp M, Barton GJ. Jalview Version 2-a multiple sequence alignment editor and analysis workbench. Bioinformatics 2009; 25: 1189-91.